Avantax Advisory Services Inc. Makes New Investment in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Avantax Advisory Services Inc. bought a new stake in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 30,570 shares of the company’s stock, valued at approximately $1,218,000.

A number of other hedge funds have also recently modified their holdings of the business. Drive Wealth Management LLC purchased a new position in Aligos Therapeutics during the 4th quarter valued at $916,000. Golden State Wealth Management LLC bought a new stake in shares of Aligos Therapeutics during the fourth quarter worth $107,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Aligos Therapeutics by 19.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company’s stock valued at $569,000 after purchasing an additional 2,306 shares during the period. Finally, AlphaMark Advisors LLC increased its stake in Aligos Therapeutics by 1,000.0% in the 4th quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock worth $44,000 after buying an additional 1,000 shares during the period. Institutional investors own 60.43% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright dropped their target price on shares of Aligos Therapeutics from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th.

Aligos Therapeutics Stock Down 7.8 %

ALGS opened at $10.76 on Wednesday. Aligos Therapeutics, Inc. has a 52 week low of $6.76 and a 52 week high of $46.80. The company has a market capitalization of $65.79 million, a P/E ratio of -0.81 and a beta of 2.52. The stock’s fifty day moving average is $22.97 and its two-hundred day moving average is $20.46.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Monday, March 10th. The company reported ($13.08) earnings per share for the quarter, missing the consensus estimate of ($2.63) by ($10.45). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The firm had revenue of $0.63 million during the quarter, compared to the consensus estimate of $0.43 million. During the same quarter in the previous year, the firm earned ($5.50) earnings per share. Equities analysts anticipate that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.

Aligos Therapeutics Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).